• Kiniksa Pharmaceuticals held its annual shareholder meeting on May 29, 2026.
• Shareholders backed the reappointment of three Class II directors, setting their terms to run through the 2029 annual meeting.
• PwC’s appointment as UK statutory auditor was approved through the close of the next annual meeting.
• PwC was also ratified as US independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders authorized the audit committee to set PwC’s UK statutory audit fees, also receiving the 2025 UK statutory annual accounts and report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001730430-26-000029), on May 29, 2026, and is solely responsible for the information contained therein.